# Evaluation of the Phased Radio Frequency Ablation System

Study · id `cardio:ct-nct01693120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01693120](<https://clinicaltrials.gov/study/NCT01693120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01693120

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 199 participants.

## Technical summary

Registry record NCT01693120. Allocation not applicable; no masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2017-02-07 (actual). Results posted on 2018-03-22.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 199 participants (enrolled count; ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Primary completion: 2017-02-07 (actual) (ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Completion: 2017-02-07 (actual) (ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Results first posted: 2018-03-22 (ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Countries: United States; Canada; Hungary; Netherlands; United Kingdom (ClinicalTrials.gov record NCT01693120, source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01693120-2025-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Phased Radio Frequency Ablation System
- Acronym: VICTORY-AF
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Medtronic Phased RF Ablation System
- Lead sponsor: Medtronic Cardiac Ablation Solutions
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Ablation Solutions (`cardio:org-medtronic-cardiac-ablation-solutions`)

## Provenance

Content hash: d284cc9ab2fd8abf8126f2402c1acdbc53b775cd36fc96396700b2cddca87b3b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
